ELDN

SEC source: 0000947871-19-000336 · ownership.xml · derivative · entry 2

Chimovits Erez · CIK 0001706399 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 646,204

Underlying: Common Stock · 646,204 shares

Expires 2020-11-02

F2 · derivative.exercise_price: Warrants ("Warrants") to purchase shares of the Issuer's common stock ("Shares"). The Warrants are immediately exercisable and have an exercise price of $4.00 per Share.

F2 · price: Warrants ("Warrants") to purchase shares of the Issuer's common stock ("Shares"). The Warrants are immediately exercisable and have an exercise price of $4.00 per Share.

F1 · ownership.nature: The Reporting Person is the designated representative of OrbiMed Israel GP Ltd. on the Issuer's Board of Directors. The reportable securities are owned directly by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any.

SEC source: 0000947871-19-000336 · ownership.xml · nonDerivative · entry 1

Chimovits Erez · CIK 0001706399 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,183,314

F1 · ownership.nature: The Reporting Person is the designated representative of OrbiMed Israel GP Ltd. on the Issuer's Board of Directors. The reportable securities are owned directly by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any.

SEC source: 0000947871-19-000337 · ownership.xml · derivative · entry 3

OrbiMed Israel GP Ltd. · CIK 0001569590 · Director · 10% owner

OrbiMed Israel BioFund GP Limited Partnership · CIK 0001569821 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 646,204

Underlying: Common Stock · 646,204 shares

Expires 2024-05-02

F3 · derivative.exercise_price: Warrants ("Warrants") to purchase shares of the Issuer's common stock ("Shares"). The Warrants are immediately exercisable and have an exercise price of $4.00 per Share.

F3 · price: Warrants ("Warrants") to purchase shares of the Issuer's common stock ("Shares"). The Warrants are immediately exercisable and have an exercise price of $4.00 per Share.

F1 · ownership.nature: These securities are owned directly by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power with respect to the securities held by OIP and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Erez Chimovits, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.

SEC source: 0000947871-19-000337 · ownership.xml · derivative · entry 2

OrbiMed Israel GP Ltd. · CIK 0001569590 · Director · 10% owner

OrbiMed Israel BioFund GP Limited Partnership · CIK 0001569821 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 646,204

Underlying: Common Stock · 646,204 shares

Expires 2020-11-02

F3 · derivative.exercise_price: Warrants ("Warrants") to purchase shares of the Issuer's common stock ("Shares"). The Warrants are immediately exercisable and have an exercise price of $4.00 per Share.

F3 · price: Warrants ("Warrants") to purchase shares of the Issuer's common stock ("Shares"). The Warrants are immediately exercisable and have an exercise price of $4.00 per Share.

F1 · ownership.nature: These securities are owned directly by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power with respect to the securities held by OIP and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Erez Chimovits, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.

SEC source: 0000947871-19-000337 · ownership.xml · nonDerivative · entry 1

OrbiMed Israel GP Ltd. · CIK 0001569590 · Director · 10% owner

OrbiMed Israel BioFund GP Limited Partnership · CIK 0001569821 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,183,314

F1 · ownership.nature: These securities are owned directly by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power with respect to the securities held by OIP and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Erez Chimovits, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.

SEC source: 0000919574-19-003096 · ownership.xml · nonDerivative · entry 1

LIFESCI INDEX PARTNERS LLC · CIK 0001734312 · 10% owner

YOOK PAUL · CIK 0001735029 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,065,867

F1 · ownership.nature: The Common Stock is held in the accounts of private investment funds managed by LifeSci Index Partners LLC and may be deemed to be beneficially owned by Paul Yook, a principal of LifeSci Index Partners LLC. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and affirmatively disclaims being a "group" for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.

SEC source: 0000899243-19-008141 · doc4.xml · derivative · entry 3

TURKEL CATHERINE C. · CIK 0001705278 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2029-03-14

F2 · derivative.exercise_date: This option represents a right to purchase a total of 50,000 shares of the Issuer's Common Stock, which will vest in equal quarterly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through each vesting date.

SEC source: 0000899243-19-008141 · doc4.xml · nonDerivative · entry 1

TURKEL CATHERINE C. · CIK 0001705278 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,199

F1 · price: This represents restricted stock units representing the right to receive shares of the Issuer's Common Stock, which will vest in full on the later of achievement of a performance-related goal or the first anniversary of the grant date.

SEC source: 0000899243-19-008140 · doc4.xml · derivative · entry 2

FLESHER GREGORY J. · CIK 0001705287 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2029-03-14

F2 · derivative.exercise_date: This option represents a right to purchase a total of 90,000 shares of the Issuer's Common Stock, which will vest in equal quarterly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through each vesting date.

SEC source: 0000899243-19-008140 · doc4.xml · nonDerivative · entry 1

FLESHER GREGORY J. · CIK 0001705287 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 171,556

F1 · price: This represents restricted stock units representing the right to receive shares of the Issuer's Common Stock, which will vest in full on the later of achievement of a performance-related goal or the first anniversary of the grant date.

SEC source: 0000899243-19-008139 · doc4.xml · derivative · entry 1

Kuwahara Jon · CIK 0001664784 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2029-03-14

F1 · derivative.exercise_date: This option represents a right to purchase a total of 25,000 shares of the Issuer's Common Stock, which will vest in equal quarterly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through each vesting date.

SEC source: 0000899243-18-024470 · doc4.xml · nonDerivative · entry 2

TURKEL CATHERINE C. · CIK 0001705278 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,199

F2 · price: This transaction was executed in multiple trades at prices ranging from $4.97 to $5.04. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0000899243-18-024470 · doc4.xml · nonDerivative · entry 1

TURKEL CATHERINE C. · CIK 0001705278 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,567

F1 · price: This transaction was executed in multiple trades at prices ranging from $4.47 to $4.70. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0000899243-18-024043 · doc4.xml · nonDerivative · entry 1

TURKEL CATHERINE C. · CIK 0001705278 · President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse's IRA

Disclosed balance after: 805

SEC source: 0000899243-18-016654 · doc4.xml · derivative · entry 1

LYONS GARY A · CIK 0001123343 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,100

Underlying: Common Stock · 9,100 shares

Expires 2028-06-13

SEC source: 0000899243-18-016652 · doc4.xml · derivative · entry 1

McBride John S. · CIK 0001618251 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,100

Underlying: Common Stock · 9,100 shares

Expires 2028-06-13

SEC source: 0000899243-18-016655 · doc4.xml · derivative · entry 1

Cohen Cheryl · CIK 0001529371 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,100

Underlying: Common Stock · 9,100 shares

Expires 2028-06-13

SEC source: 0000899243-18-016653 · doc4.xml · derivative · entry 1

Katkin Keith · CIK 0001314596 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,100

Underlying: Common Stock · 9,100 shares

Expires 2028-06-13

SEC source: 0000899243-18-007648 · doc4.xml · derivative · entry 2

Kuwahara Jon · CIK 0001664784 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2028-03-13

F2 · derivative.exercise_date: This option represents a right to purchase a total of 12,000 shares of the Issuer's Common Stock, one quarter of which will become fully vested and exercisable on March 13, 2019, with the remaining 9,000 shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.

SEC source: 0000899243-18-007648 · doc4.xml · nonDerivative · entry 1

Kuwahara Jon · CIK 0001664784 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,250

F1 · price: This represents restricted stock units representing the right to receive shares of the Issuer's Common Stock, which will vest in full on the later of achievement of a performance-related goal or the first anniversary of the grant date.

SEC source: 0000899243-18-007647 · doc4.xml · derivative · entry 2

FLESHER GREGORY J. · CIK 0001705287 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,500

Underlying: Common Stock · 56,500 shares

Expires 2028-03-13

F2 · derivative.exercise_date: This option represents a right to purchase a total of 56,500 shares of the Issuer's Common Stock, one quarter of which will become fully vested and exercisable on March 13, 2019, with the remaining 42,375 shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.

SEC source: 0000899243-18-007647 · doc4.xml · nonDerivative · entry 1

FLESHER GREGORY J. · CIK 0001705287 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,556

F1 · price: This represents restricted stock units representing the right to receive shares of the Issuer's Common Stock, which will vest in full on the later of achievement of a performance-related goal or the first anniversary of the grant date.

SEC source: 0000899243-18-007642 · doc4.xml · derivative · entry 2

TURKEL CATHERINE C. · CIK 0001705278 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2028-03-13

F2 · derivative.exercise_date: This option represents a right to purchase a total of 24,000 shares of the Issuer's Common Stock, one quarter of which will become fully vested and exercisable on March 13, 2019, with the remaining 18,000 shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.

SEC source: 0000899243-18-007642 · doc4.xml · nonDerivative · entry 1

TURKEL CATHERINE C. · CIK 0001705278 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,519

F1 · price: This represents restricted stock units representing the right to receive shares of the Issuer's Common Stock, which will vest in full on the later of achievement of a performance-related goal or the first anniversary of the grant date.

SEC source: 0000899243-17-025437 · doc4.xml · derivative · entry 1

TURKEL CATHERINE C. · CIK 0001705278 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2027-11-06

F1 · derivative.exercise_date: This option represents a right to purchase a total of 50,000 shares of the Issuer's Common Stock one quarter of which will become fully vested and exercisable on 11/6/2018, with the remaining 37,500 shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.

SEC source: 0000899243-17-018152 · doc4.xml · derivative · entry 1

Kuwahara Jon · CIK 0001664784 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2027-07-10

F1 · derivative.exercise_date: This option represents a right to purchase a total of 35,000 shares of the Issuer's Common Stock one quarter of which will become fully vested and exercisable on 7/10/2018, with the remaining 26,250 shares vesting in equal quarterly installments over the following three years.

SEC source: 0000899243-17-017767 · doc4.xml · derivative · entry 1

LYONS GARY A · CIK 0001123343 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2027-06-30

F1 · derivative.exercise_date: This option represents a right to purchase a total of 18,000 shares of the Issuer's Common Stock. The shares will vest ratably each quarter over three years beginning on June 30, 2017.

SEC source: 0000899243-17-017764 · doc4.xml · derivative · entry 1

McBride John S. · CIK 0001618251 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2027-06-30

F1 · derivative.exercise_date: This option represents a right to purchase a total of 18,000 shares of the Issuer's Common Stock. The shares will vest ratably each quarter over three years beginning on June 30, 2017.

SEC source: 0000899243-17-017761 · doc4.xml · derivative · entry 1

Morrison Jodie Pope · CIK 0001618247 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2027-06-30

F1 · derivative.exercise_date: This option represents a right to purchase a total of 18,000 shares of the Issuer's Common Stock. The shares will vest ratably each quarter over three years beginning on June 30, 2017.

SEC source: 0000899243-17-017762 · doc4.xml · derivative · entry 1

Cohen Cheryl · CIK 0001529371 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2027-06-30

F1 · derivative.exercise_date: This option represents a right to purchase a total of 18,000 shares of the Issuer's Common Stock. The shares will vest ratably each quarter over three years beginning on June 30, 2017.

SEC source: 0000899243-17-017760 · doc4.xml · derivative · entry 1

Katkin Keith · CIK 0001314596 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,000

Underlying: Common Stock · 36,000 shares

Expires 2027-06-30

F1 · derivative.exercise_date: This option represents a right to purchase a total of 36,000 shares of the Issuer's Common Stock. The shares will vest ratably each quarter over three years beginning on June 30, 2017.

SEC source: 0000899243-17-014541 · doc4.xml · derivative · entry 1

TURKEL CATHERINE C. · CIK 0001705278 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,500

Underlying: Common Stock · 52,500 shares

Expires 2027-05-23

F1 · derivative.exercise_date: This option represents a right to purchase a total of 52,500 shares of the Issuer's Common Stock. 36,000 shares will vest ratably each month over three years beginning on May 24, 2017 (the "grant date"). 16,500 shares will vest on the later of achievement of a performance-related goal or the first anniversary of the grant date.

SEC source: 0000899243-17-014542 · doc4.xml · derivative · entry 1

FLESHER GREGORY J. · CIK 0001705287 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2027-05-23

F1 · derivative.exercise_date: This option represents a right to purchase a total of 250,000 shares of the Issuer's Common Stock. 150,000 shares will vest ratably each month over three years beginning on May 24, 2017 (the "grant date"). 100,000 shares will vest on the later of achievement of a performance-related goal or the first anniversary of the grant date.

SEC source: 0000899243-17-014539 · doc4.xml · derivative · entry 1

OCAMPO CHRISTINE · CIK 0001280154 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,500

Underlying: Common Stock · 52,500 shares

Expires 2027-05-23

F1 · derivative.exercise_date: This option represents a right to purchase a total of 52,500 shares of the Issuer's Common Stock. 36,000 shares will vest ratably each month over three years beginning on May 24, 2017 (the "grant date"). 16,500 shares will vest on the later of achievement of a performance-related goal or the first anniversary of the grant date.

SEC source: 0000899243-17-012936 · doc4.xml · nonDerivative · entry 1

FLESHER GREGORY J. · CIK 0001705287 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,856

F1 · shares: All numbers give effect to the 1:9 reverse stock split effected by the Issuer on May 11, 2017.

F1 · balance_after: All numbers give effect to the 1:9 reverse stock split effected by the Issuer on May 11, 2017.

SEC source: 0000899243-17-012930 · doc4.xml · nonDerivative · entry 1

OCAMPO CHRISTINE · CIK 0001280154 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,590

F1 · shares: All numbers give effect to the 1:9 reverse stock split effected by the Company on May 11, 2017.

F1 · balance_after: All numbers give effect to the 1:9 reverse stock split effected by the Company on May 11, 2017.

SEC source: 0000899243-17-012934 · doc4.xml · nonDerivative · entry 1

TURKEL CATHERINE C. · CIK 0001705278 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,519

F1 · shares: All numbers give effect to the 1:9 reverse stock split effected by the Company on May 11, 2017.

F1 · balance_after: All numbers give effect to the 1:9 reverse stock split effected by the Company on May 11, 2017.

SEC source: 0000899243-17-012816 · doc4.xml · nonDerivative · entry 1

OrbiMed Israel GP Ltd. · CIK 0001569590 · Director · 10% owner

OrbiMed Israel BioFund GP Limited Partnership · CIK 0001569821 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,537,110

F1 · kind: Received in exchange for 3,898,632 shares of Otic Pharma, Ltd. Series B Preferred Shares, 816,954 shares of Series C Preferred Shares and 96,637 shares of Ordinary Shares in connection with the closing of the share purchase transaction with Otic Pharma, Ltd. All numbers give effect to the 9:1 reverse stock split effected by the Company on May 11, 2017 (the "Reverse Stock Split").

F1 · price: Received in exchange for 3,898,632 shares of Otic Pharma, Ltd. Series B Preferred Shares, 816,954 shares of Series C Preferred Shares and 96,637 shares of Ordinary Shares in connection with the closing of the share purchase transaction with Otic Pharma, Ltd. All numbers give effect to the 9:1 reverse stock split effected by the Company on May 11, 2017 (the "Reverse Stock Split").

F2 · ownership.nature: The reportable securities are owned directly by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and as a result may be deemed to have beneficial ownership over such securities.

F3 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Erez Chimovits, to serve on the Issuer's board of directors. This report on Form 4 shall not be deemed an admission that any such entity or person, including the Reporting Persons, is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.